Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine withdrawal study in multiple sclerosis
ACTRN12613000439741Phase 4Not yet recruiting
- Sponsor
- Austin Health
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind, single-arm trial of dalfampridine in multiple sclerosis (MS), sponsored by Austin Health. Primary endpoint: Correlation between clinical and electrophysiological findings on versus off fampridine. Planned start May 2013; status: not yet recruiting.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12613000439741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000439741.